Table 4.
Multivariate analysis of variables associated with change in GFRa)
| Variable | OR | 95% CI | p-value |
|---|---|---|---|
| Type of treatment | |||
| Gemcitabine | 1 (reference) | ||
| Cisplatin | 2.425 | 1.211–4.858 | 0.012 |
| No. of comorbidities | |||
| 1 | 1 (reference) | ||
| ≥ 2 | 0.659 | 0.301–1.444 | 0.298 |
| Clinical stage | |||
| IB2, IIA, IIB | 1 (reference) | ||
| IIIA, IIIB, IVB | 1.446 | 0.718–2.912 | 0.301 |
| Age | 0.975 | 0.946–1.004 | 0.095 |
CI, confidence interval; GFR, glomerular filtrationrate; OR, odds ratio.
a)
Assessed with the Chronic Kidney Disease Epidemiology Collaboration formula (mL/min/1.73 m2).